Connect Biopharma (CNTB) Stock Price, News & Analysis

Company Overview

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Key Stats

• Today's Range: $0.95 to $0.96
• 50-Day Range: $0.95 to $1.40
• 52-Week Range: $0.77 to $2.66
• Volume: 10,220 shs
• Average Volume: 76,426 shs
• Market Capitalization: $52.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

Connect Biopharma Stock Analysis - MarketRank™

Connect Biopharma scored higher than 69% of companies evaluated by MarketBeat, and ranked 323rd out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Connect Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Connect Biopharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Connect Biopharma has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.11% of the float of Connect Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Connect Biopharma has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Connect Biopharma has recently decreased by 7.44%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Connect Biopharma does not currently pay a dividend.

Dividend Growth

Connect Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.11% of the float of Connect Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Connect Biopharma has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Connect Biopharma has recently decreased by 7.44%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Connect Biopharma has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Connect Biopharma this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Connect Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.60% of the stock of Connect Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

58.72% of the stock of Connect Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CNTB Stock Analysis - Frequently Asked Questions

How have CNTB shares performed this year?

Connect Biopharma's stock was trading at $1.18 at the start of the year. Since then, CNTB shares have decreased by 19.4% and is now trading at $0.9509.
View the best growth stocks for 2024 here.

When did Connect Biopharma IPO?

Connect Biopharma (CNTB) raised $150 million in an initial public offering on Friday, March 19th 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC acted as the underwriters for the IPO.

Who are Connect Biopharma's major shareholders?

Top institutional shareholders of Connect Biopharma include BML Capital Management LLC (3.79%).

How do I buy shares of Connect Biopharma?

Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Connect Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Connect Biopharma investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Builders FirstSource (BLDR) and CymaBay Therapeutics (CBAY).

Company Calendar

• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CNTB
• CUSIP: N/A
• CIK: 1835268
• Web: www.connectbiopharm.com
• Phone: 18587271045
• Fax: +1 8586147007
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $8.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +741.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.04
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $24.12 million
• Price / Sales: 2.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.83 per share
• Price / Book: 0.52

Miscellaneous

• Outstanding Shares: 55,254,000
• Free Float: 42,767,000
• Market Cap: $52.54 million
• Optionable: Optionable
• Beta: -0.34